PepTalk 2017
PepTalk 2017
2014 Archived Content

Cambridge Healthtech Institute’s Third Annual
Bispecific Antibody Therapeutics
Engineering Multispecificity
January 16-17, 2014

Creating bioactive molecules that are multivalent and multifunctional offers the promise of more effective therapeutics. By binding to at least two molecular targets simultaneously, antibodies are empowered, thereby delivering a highly potent therapeutic, particularly for cancer immunotherapy. This meeting will explore the challenges of engineering multispecificity to ensure stability and efficacy, and will review the numerous forms of multispecific antibodies.  Safety issues will be given particular focus, as will PK and immunogenicity. Case studies will be presented that highlight preclinical development, as well as clinical data. Join colleagues from around the world in this discussion of the exciting breakthroughs in engineering antibodies, and see how cancer and other applications are advancing into a true therapeutic revolution.

Day 1 | Day 2 | Download Engineering Brochure | Speaker Biographies  


1:00-1:45 pm Conference Registration

New Approaches for Creating
Efficacious Bispecifics

2:00 Chairperson’s Opening Remarks

Michael J. Feldhaus, Ph.D., Co-Founder and CEO, Arus Biologics

Keynote Presentation

2:05 Teaching Antibodies New Tricks: From Simulation to Clinical Benefits of Bispecific Antibodies

Ulrik NielsenUlrik Nielsen, Ph.D., CSO, Merrimack Pharmaceuticals

Bispecific antibodies offer the potential to create highly specific therapeutics with greater potency and even have the ability to inhibit multiple targets. This makes the therapeutic design process extremely complex because specificity, affinity and valency all need to be optimized in parallel. In our design process, we employ computational network models to engineer bispecific antibodies that embrace these complexities and address issues of tumor cell heterogeneity and network redundancies. We will present examples from three of Merrimack’s bispecific antibodies that are currently in development.

2:45 Safety and Efficacy Considerations in Designing Bispecific Therapeutics

Jijie GuJijie Gu, Ph.D., Senior Principal Research Scientist, Global Biologics, AbbVie Pharmaceuticals 


3:15 Bispecific Antibodies as a New Weapon in the Fight Against Antibiotic-Resistant Bacterial Pathogens

G. Jonah RaineyG. Jonah Rainey, Ph.D., Senior Scientist, ADPE/Research, MedImmune, LLC

Pseudomonas aeruginosa infections are difficult to treat due to bacterial adaptation and persistence in response to environmental, antibiotic or host defensive pressures. We identified a novel bispecific antibody format with superior activity in vitro and multiple animal models compared to previously described platforms. The BsAb employs multiple mechanisms and provides broad strain coverage, showing synergy between the two specificities and when used with sub-protective doses of antibotics. This BsAb is developable as a therapeutic in terms of production, purification, and stability.

3:45 Extended Q&A

4:00 Refreshment Break in the Exhibit Hall with Poster Viewing

4:45 A Novel Modular Antibody Technology for Generating Bispecific Antibodies

MihiribanTunaMihriban Tuna, Ph.D., Vice President, Discovery, F-star

Introduction of novel binding sites into the CH3 domain of the Fc region provides an elegant approach to generating bispecific antibodies. These Fc regions with antigen binding (“Fcabs”) can be very rapidly introduced into any existing antibody to create an effectively unlimited number of different target combinations. This presentation will describe how F-star is harnessing the power of this technology to generate a pipeline of bispecific antibodies for the treatment of cancer.

5:15 Targeting Cancer Stem Cells with a Multispecific Antibody

Christopher L. ReyesChristopher L. Reyes, Vice President, Research and Development Biologics, Bionomics

Using our validated CSC Rx Discovery platform, we have developed a novel antibody that simultaneously targets two cancer stem cell receptors. This multispecific antibody (MsAb) is a conventional human IgG1 that was developed to bind to two receptors with high affinity for increased targeting and activity. Pre-clinical studies have shown a reduction in cancer stem cell populations in multiple tumor mouse models.

5:45 Close of Day

Day 1 | Day 2 | Download Engineering BrochureSpeaker Biographies